Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Bayer's Phase 3 ARANOTE trial showed darolutamide plus androgen deprivation therapy (ADT) reduced the risk of radiological ...
Roivant Sciences has licensed worldwide rights to develop and commercialize Bayer's mosliciguat for an upfront payment of $...
BridgeBio Pharma presented additional data from its Phase 3 ATTRibute-CM study of acoramidis in ATTR-CM at the European Society...
Australian judge dismisses class action lawsuit against Bayer for Roundup causing cancer. Ruling supports company's stance ...
Pennsylvania judge cuts Bayer's $2.25 billion Roundup verdict to $400 million. Both Bayer and plaintiff plan appeals in the...
European equities up, ECB likely to cut rates in June, traders confident. Euro slightly higher. Top performers: RWE, Bayer, VW,...
Cencora reports a cyberattack exposing sensitive medical information, including patient names, addresses, birth dates, diagnose...
Bayer to present detailed Phase 3 OASIS 1 and 2 study results showing elinzanetant significantly reduces moderate to severe men...
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will...
